Bomedemstat + Atezolizumab
Phase 1/2Terminated 3 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive Stage Lung Small Cell Carcinoma
Conditions
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
Trial Timeline
Apr 11, 2022 → Apr 5, 2024
NCT ID
NCT05191797About Bomedemstat + Atezolizumab
Bomedemstat + Atezolizumab is a phase 1/2 stage product being developed by Merck for Extensive Stage Lung Small Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05191797. Target conditions include Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma.
What happened to similar drugs?
0 of 11 similar drugs in Extensive Stage Lung Small Cell Carcinoma were approved
Approved (0) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05191797 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Extensive Stage Lung Small Cell Carcinoma